This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pfizer Inc.

Drug Names(s): LUV, large unilamellar vesicles

Description: ETC-588 is an intravenous agent made of naturally occurring lipids (eggphosphatidylcholine) and circulates through arteries to remove cholesterol and other lipids from peripheral tissues and the arterial wall. Esperion believes that ETC-588 augments high-density lipoprotein (HDL) function for the acute or sub-acute treatment of acute coronary syndromes.

Deal Structure: In March 1999, Esperion exclusively licensed certain LUV technology from Inex on a worldwide basis. Inex owns granted patents in 13 European countries covering the LUV technology and exclusively licenses, from the University of British Columbia, two issued U.S. patents and one pending U.S. patent application. The European patents claim methods for treatment ofatherosclerosis using liposomes. The U.S. patents and patent application claim liposome structure and chemical makeup and methods for treatment of disease, including atherosclerosis. The U.S. patents expire no earlier than 2014. TheEuropean patents expire in 2011.

The license agreement with Inex, as amended,requires Esperion to make payments to Inex as milestones are achieved, and to pay Inexroyalties on sales of products that are covered by the licensed patents or developed using the licensed technology. This license continues until the later of ten years from the first commercial sale of a product covered by this license or...See full deal structure in Biomedtracker

Partners: Arbutus Biopharma Corporation

ETC-588 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug